US Government Payer–Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

US Government Payer–Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?

Published:2023-05-10 Issue:14 Volume:41 Page:2488-2492
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Strohbehn Garth W.¹²³⁴^ORCID,Lichter Allen S.⁴^ORCID,Ratain Mark J.⁴⁵⁶⁷^ORCID

Affiliation:

1. Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI

2. LTC Charles S Kettles VA Medical Center, Ann Arbor, MI

3. University of Michigan Rogel Cancer Center, Ann Arbor, MI

4. Optimal Cancer Care Alliance, Ann Arbor, MI

5. University of Chicago, Chicago, IL

6. University of Chicago Medicine, Chicago, IL

7. Center for Personalized Therapeutics, The University of Chicago, Chicago, IL

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.02049

Reference33 articles.

1. The Drug-Dosing Conundrum in Oncology — When Less Is More

2. Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value

3. Inflation Reduction Act and US drug pricing

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Using Interventional Pharmacoeconomic Clinical Trials and Outcomes-Based Contracts to Repurpose Generic Drugs with Cost-Savings;Drug Repurposing;2024-07-03

2. Projected environmental and public health benefits of extended-interval dosing: an analysis of pembrolizumab use in a US national health system;The Lancet Oncology;2024-06

3. Innovative Dosierungsoptimierung in der Onkologie;Onkologische Welt;2024-03

4. ‘Contribution of component’ and the perioperative immune-checkpoint inhibitor precedent;Nature Reviews Clinical Oncology;2024-01-05

5. Optimizing the doses of cancer drugs after usual dose finding;Clinical Trials;2023-12-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3